Wednesday, January 15

Tag: Sarepta Therapeutics

Nov282024 by adminNo Comments
Biotech ETF (XBI) ended a diagonal– Looking for purchasing dips

Biotech ETF (XBI) ended a diagonal– Looking for purchasing dips

Business
The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that tracks the biotechnology section of the S&P Total Market Index. This ETF permits financiers to acquire direct exposure to big, mid, and small-cap biotech stocks. If you're interested in biotechnology, XBI might be worth checking out even more. Here are a few of its leading holdings and their portion weights: United Therapeutics Corporation (UTHR): 2.92%. Precise Sciences Corporation (EXAS): 2.91%. Gilead Sciences, Inc. (GILD): 2.89%. Sarepta Therapeutics, Inc. (SRPT): 2.87%. Amgen Inc. (AMGN): 2.84%. Alnylam Pharmaceuticals, Inc. (ALNY): 2.65%. Regeneron Pharmaceuticals, Inc. (REGN): 2.64%. Vertex Pharmaceuticals Incorporated (VRTX): 2.60%. AbbVie Inc. (ABBV): 2.60%. BioMarin Pharmaceutical Inc. (BMRN): 2.56%. In July, we desc...
Read More
Mar22024 by adminNo Comments
United States FDA to Review Sarepta’s Duchenne Gene Therapy for Traditional Approval

United States FDA to Review Sarepta’s Duchenne Gene Therapy for Traditional Approval

Health and Mediacal
(Reuters) - Sarepta Therapeutics stated on Friday that the United States FDA would evaluate an application looking for standard approval for its gene treatment to deal with a muscle-wasting condition by June 21, months after it stopped working the primary objective of a confirmatory trial. Shares of the business increased almost 11% in early morning trading. They quickly fell in October after information from the confirmatory research study, however have actually recuperated losses ever since. The business likewise stated that the FDA did not strategy to hold a conference of its outdoors professionals to talk about the brand-new application. William Blair expert Tim Lugo stated the absence of an advisory committee conference is a favorable indication. A conventional approval represents a $...
Read More